Department of Ultrasound, China-Japan Friendship Hospital, Beijing, 100029, China.
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Endocrine. 2023 Jun;80(3):552-562. doi: 10.1007/s12020-022-03286-3. Epub 2022 Dec 21.
Fine-needle aspiration (FNA) biopsy is an effective method to discriminate malignant thyroid nodules but reaches indeterminate results in approximately 30% of cases. Molecular testing can improve the diagnostic accuracy of FNA. This study aimed to investigate the real-life utility of the five-gene panel testing in thyroid FNAs.
759 thyroid nodules from 740 patients under FNAs were retrospectively enrolled. Gene mutation information and clinical parameters, including age, gender, tumor size, and lymph node metastasis, were respectively recorded. Cytological results were classified based on The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC). We analyzed mutational hotspots in BRAF, KRAS, NRAS, HRAS, and TERT genes from FNA specimens. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were calculated to assess diagnostic performance.
We identified 549 five-gene mutations in 759 nodules (72.3%), and the mutation frequency increased from the lower TBSRTC category to the upper category. BRAF.p.V600E showed the highest mutation incidence (71.3%) in the five-gene panel, correlated with the small to medium diameter (p = 0.008, p = 0.012) and high cytological categories (p < 0.001). The sensitivity, specificity, PPV, NPV, and accuracy of the combination of FNA cytology and five-gene detection were 96.83%, 100%, 100%, 42.86%, and 96.90%, respectively.
The mutation frequency of the five-gene panel is 72.3% in thyroid FNAs. BRAF.p.V600E has the highest alteration rate, which is closely associated with tumor size and cytological results. The five-gene panel can improve the sensitivity and accuracy of FNA cytology, which may represent a valid adjunct technique in distinguishing thyroid nodules.
细针穿刺活检(FNA)是鉴别恶性甲状腺结节的有效方法,但在约 30%的病例中得出不确定的结果。分子检测可以提高 FNA 的诊断准确性。本研究旨在探讨五基因 panel 检测在甲状腺 FNA 中的实际应用。
回顾性纳入 740 例患者的 759 个甲状腺结节进行 FNA。分别记录基因突变信息和临床参数,包括年龄、性别、肿瘤大小和淋巴结转移。根据甲状腺细胞病理学报告的 Bethesda 系统(TBSRTC)对细胞学结果进行分类。我们分析了 FNA 标本中 BRAF、KRAS、NRAS、HRAS 和 TERT 基因的突变热点。计算敏感性、特异性、阳性预测值(PPV)、阴性预测值(NPV)和准确性,以评估诊断性能。
我们在 759 个结节中鉴定出 549 个五基因突变(72.3%),突变频率从较低的 TBSRTC 类别增加到较高的类别。五基因 panel 中 BRAF.p.V600E 的突变发生率最高(71.3%),与中小直径(p=0.008,p=0.012)和高细胞学分类(p<0.001)相关。FNA 细胞学和五基因检测联合的敏感性、特异性、PPV、NPV 和准确性分别为 96.83%、100%、100%、42.86%和 96.90%。
甲状腺 FNA 中五基因 panel 的突变频率为 72.3%。BRAF.p.V600E 的改变率最高,与肿瘤大小和细胞学结果密切相关。五基因 panel 可提高 FNA 细胞学的敏感性和准确性,可能是鉴别甲状腺结节的有效辅助技术。